Drugs / Ga-68-NGUL
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05547061 | Apr 2021 → Dec 2024 overdue | castration-resistant prostate carcinoma | Cellbion Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ga-68-NGUL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05547061 ↗ |
| Modality | Diagnostic / imaging agent | “diagnostic validity/safety of Ga-68-NGUL” NCT05547061 ↗ |
| Route | Intravenous | “Administered intravenously during screening and every 12 weeks after the first administration of Lu-177-DGUL.” NCT05547061 ↗ |